U.S. Pharmaceutical Tariffs Stir Global Impact and Patient Harm Concerns

The imposition of 100% tariffs on the U.S. pharmaceutical industry by President Donald Trump has triggered global concerns over production and supply chains, particularly affecting patient access to medicines. The Swiss pharmaceutical body urged the government to secure a tariff-free deal similar to Britain's agreement.

President Donald Trump's decision to implement 100% tariffs on the U.S. pharmaceutical industry has sparked warnings from global health bodies. Switzerland's pharmaceutical association, interpharma, expressed concerns on Friday, stating that these tariffs threaten production and supply chains, significantly impacting patient access to critical medications.

The Swiss government is being urged to negotiate a tariff-free agreement akin to the one the UK recently finalized. The British deal grants tariff-free access to the U.S. pharmaceutical market following an executive order from Trump, making the UK the sole beneficiary of such an agreement so far.

Industry experts warn that these tariffs could create significant barriers for pharmaceutical companies and potentially introduce new costs at a time when the global economy is already under stress due to escalating energy prices.

(With inputs from agencies.)